Skip to main content
main-content

The independent medical news service

Colorectal cancer

29-11-2018 | Colorectal cancer | News | Article

Rechallenge with cetuximab, irinotecan may benefit mCRC patients

Approximately one-fifth of patients with RAS and BRAF wild-type metastatic colorectal cancer derive clinical benefit from rechallenge with cetuximab plus irinotecan, Italian researchers report.

Source:

JAMA Oncol 2018; doi:10.1001/jamaoncol.2018.5080

06-11-2018 | Oncology | Main feed | News

NCRI 2018

Run-in period may improve adherence to aspirin for chemoprevention

In patients undergoing radical therapy for cancer, an 8-week run-in period of aspirin is acceptable and well tolerated, and could reduce the risk for nonadherence and participant attrition in adjuvant and prevention trials, say researchers.

Source:

NCRI 2018; Glasgow, UK

11-10-2018 | Oncology | Main feed | News

Screen-detected colon cancer patients experience fewer complications

Patients whose colon cancers are detected by routine screening have fewer postoperative complications than individuals whose cancers are diagnosed outside of a national programme, study findings indicate.

Source:

JAMA Surg 2018; doi:10.1001/jamasurg.2018.3567

01-08-2018 | Oncology | News | Article

Benefits of laparoscopic surgery for colorectal liver metastases highlighted

Minimally invasive liver surgery is associated with less postoperative morbidity, fewer major complications, and shorter hospital stays than open surgery among patients with colorectal liver metastases, Italian researchers report.

Source:

JAMA Surg 2018; doi:10.1001/jamasurg.2018.2107

03-07-2018 | Colorectal cancer | Main feed | News

Fruquintinib prolongs metastatic CRC survival

Phase III trial results indicate that third- or later-line treatment with fruquintinib leads to significantly improved overall survival in Chinese patients with metastatic colorectal cancer.

Source:

JAMA 2018; 319: 2486–2496

29-06-2018 | Colorectal cancer | News | Article

In other news: CRC and surveillance

We cover three studies of colorectal cancer surveillance, one evaluating the relationship between adenomas at colonoscopy and the long-term incidence of cancer, while the other two investigate whether higher-intensity post-surgery follow-up improves outcomes.

14-06-2018 | Colorectal cancer | News | Article

ASCO 2018

Oxaliplatin HIPEC unnecessary for colorectal peritoneal carcinomatosis patients

Oxaliplatin-based hyperthermic intraperitoneal chemotherapy after cytoreductive surgery does not improve the survival of colorectal cancer patients with peritoneal carcinomatosis, the PRODIGE 7 investigators report.

Source:

ASCO Annual Meeting 2018; Chicago, Illinois, USA

02-06-2018 | Colorectal cancer | News | Article

ASCO 2018 in brief

Metastatic CRC cost disparity revealed for USA, Canada

The cost of metastatic colorectal cancer treatment in the USA is significantly more expensive than in Canada but does not achieve a greater survival benefit among patients, highlight findings reported at the ASCO Annual Meeting 2018 in Chicago, Illinois, USA.

29-05-2018 | Colorectal cancer | News | Article

News in brief

Sex differences highlighted for CRC chemotherapy-related toxicity

Women have an increased risk for adverse events associated with fluorouracil-based chemotherapy for colorectal cancer, suggests an analysis of the PETACC-3 trial.

25-05-2018 | Colorectal cancer | News | Article

Worse prognosis for patients with V600E BRAF-mutated colorectal liver metastases

The presence of the BRAF V600E mutation in colorectal liver metastases is associated with a worse prognosis and increased risk for recurrence, according to findings from an international retrospective cohort study.

Source:

JAMA Surg 2018; Advance online publication

04-04-2018 | Colorectal cancer | News | Article

mXELIRI regimen offers alternative treatment for metastatic colorectal cancer

Treatment with a modified XELIRI regimen offers an alternative to standard second-line therapy with FOLFIRI in patients with metastatic colorectal cancer, research conducted in Asia shows.

Source:

Lancet Oncol 2018; Advance online publication

21-03-2018 | Oncology | News | Article

EU mortality rates predicted to decline for many tumor types

Mortality rates associated with most of the major cancer sites are expected to decline in the European Union in 2018, research indicates.

Source:

Ann Oncol 2018; Advance online publication

14-02-2018 | Oncology | News | Article

Early alpelisib data promising in patients with PIK3CA-altered solid tumors

Researchers report “encouraging” tolerability and efficacy results from a phase Ia trial of the oral phosphatidylinositol 3-kinase α–selective inhibitor alpelisib among patients with PIK3CA-altered advanced solid tumors.

Source:

J Clin Oncol 2018; Advance online publication

05-02-2018 | Colorectal cancer | News | Article

News in brief

Nivolumab–ipilimumab duo has potential for dMMR/MSI-H metastatic CRC

CheckMate 142 findings point to a role for dual PD-1 and CTLA-4 inhibition with nivolumab and ipilimumab in patients with previously treated metastatic colorectal cancer that is DNA mismatch repair-deficient or has high microsatellite instability.

25-01-2018 | Colorectal cancer | News | Article

News in brief

Regular PET/CT imaging fails to extend high-risk CRC patient survival

Researchers do not recommend the addition of 18F-fluorodeoxyglucose–positron emission tomography/computed tomography to a standard 3-year monitoring strategy for patients with stage II perforated, stage III, or stage IV colorectal cancer at high risk for recurrence.

24-01-2018 | Colorectal cancer | News | Article

No advantage to continuing bevacizumab after induction chemotherapy in mCRC

Maintenance treatment with bevacizumab monotherapy following induction chemotherapy has no benefit for metastatic colorectal cancer patients, PRODIGE 9 trial findings show.

Source:

J Clin Oncol 2018; Advance online publication

19-01-2018 | Colorectal cancer | News | Article

Inflammatory diet linked to CRC risk

A diet rich in foods with a high inflammatory potential is associated with a significant increase in the risk for colorectal cancer, say US researchers who collated information from more than 120,000 adults followed up over 26 years.

Source:

JAMA Oncol 2018; Advance online publication

16-11-2017 | Colorectal cancer | News | Article

Mismatch repair deficiency testing underused for CRC patients in USA

Researchers have warned that underuse of mismatch repair deficiency testing “is a persistent and pervasive problem” in the USA, even among young adults with colorectal cancer where its use is unequivocally recommended.

Source:

JAMA Oncol 2017; Advance online publication

07-11-2017 | Colorectal cancer | News | Article

Increased fiber intake benefits colorectal cancer patients

US research suggests that increasing fiber intake after a diagnosis of nonmetastatic colorectal cancer could significantly improve survival.

Source:

JAMA Oncol 2017; Advance online publication

02-11-2017 | Oncology | News | Article

Editor's pick

Robotic-assisted laparoscopic approach challenged for rectal, renal cancer patients

Research casts doubt on the benefit of robotic-assisted laparoscopic surgery for patients requiring rectal resection or radical nephrectomy, finding no significant benefits over a conventional laparoscopic approach.

Source:

JAMA 2017; 318: 1545–1547, 1561–1568, 1569–1580

image credits